Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics, Inc. (Nasdaq: AGRX) is a forward-thinking company specializing in women's healthcare. Their mission is to address the unmet health needs of today’s women by providing innovative contraceptive options. The company’s leading product, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), is a once-weekly prescription contraceptive patch that offers an alternative to daily pills or longer-acting methods. Twirla employs Agile's proprietary Skinfusion® technology designed to improve patch adhesion and patient comfort.
Recently, Agile Therapeutics has reported significant financial and operational accomplishments. In the third quarter of 2023, Twirla achieved net revenue of $6.7 million, reflecting a 21% increase from the second quarter and a 122% increase year-over-year. The company projects positive cash flow from operations by the first quarter of 2024, backed by a strong gross margin that grew to 63% in the third quarter of 2023.
The company’s strategic focus includes expanding their market presence through partnerships and promotional efforts, notably targeting five key states with high reimbursement potential. Agile is also enhancing Twirla's availability through telemedicine platforms like Nurx, TwentyEight Health, and Pandia, aiming to broaden its reach further.
Operational expenses have been managed effectively, with a reported decrease in GAAP operating expenses to $8.2 million in the third quarter of 2023. This financial discipline, alongside the anticipated revenue, positions Agile Therapeutics favorably for sustainable growth.
Additionally, Agile Therapeutics has successfully completed the pay-off of their debt facility with Perceptive Advisors, leaving their balance sheet debt-free. Despite a delisting notice from Nasdaq, the company’s shares continue to trade on the OTC Market, maintaining its focus on executing its business plan and exploring strategic opportunities to maximize Twirla’s growth and shareholder value.
For more detailed updates, latest news, and information, you can visit their website at www.agiletherapeutics.com or follow them on Twitter @agilether.
Agile Therapeutics (Nasdaq: AGRX), a women's healthcare company, announced that its CEO, Al Altomari, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:20 p.m. ET. The event will be accessible via live webcast on the Investor Relations page of Agile Therapeutics' website and will be archived for 30 days. Agile Therapeutics focuses on contraceptive solutions, including its product Twirla, a non-daily prescription contraceptive.
Agile Therapeutics (AGRX) reported its first quarter 2021 financial results, showing promising growth in Twirla prescriptions, with 1,853 total scripts by March 31, 2021, driven by an expanding base of over 850 healthcare providers. The company achieved $116,000 in net revenue, though it faced a net loss of $17.1 million, or $0.20 per share. Operating expenses rose to $15.2 million, up from $7.6 million in the prior year. Despite challenges, Agile continues efforts to broaden Twirla's market access, including securing Medicaid coverage in multiple states.
Agile Therapeutics (Nasdaq: AGRX) announced that a post hoc analysis of the Phase 3 SECURE Trial for Twirla® will be presented at ACOG Annual Meeting from April 30 to May 2, 2021. This analysis evaluates safety and efficacy in women with BMI < 25 kg/m2 and 25-30 kg/m2. Results indicate that Twirla maintains safety and tolerability in the latter group, despite lower efficacy. The findings support informed patient counseling regarding contraceptive options for women with higher BMI. Agile aims to address women’s healthcare needs through product innovation.
Agile Therapeutics (Nasdaq: AGRX) will report its first quarter 2021 financial results on May 4, 2021, after market close. A live conference call is scheduled for 4:30 p.m. EDT. Investors can join by dialing (866) 324-3683 for domestic calls or (509) 844-0959 internationally. The webcast will be available via their Investor Relations page. Agile aims to meet women's healthcare needs with its non-daily contraceptive, Twirla, utilizing proprietary Skinfusion technology.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that Chairman and CEO Al Altomari will present at two upcoming investor conferences in March 2021. The events include the H.C. Wainwright Global Life Sciences Conference, available on-demand starting March 9, 2021, and the Oppenheimer 31st Annual Virtual Healthcare Conference on March 17, 2021. Webcasts of the presentations will be accessible on Agile's website for 30 days following each conference. Agile Therapeutics focuses on women's healthcare, offering innovative contraceptive options like their product Twirla®.
Agile Therapeutics, Inc. (AGRX) reported a net loss of $17.6 million for Q4 2020, with gross revenue exceeding $1 million following the launch of Twirla®. The company has secured $45 million in credit from Perceptive Advisors, enhancing financial flexibility. Agile achieved about 40-45% commercial formulary coverage for Twirla and expects further growth through agreements with wholesalers and Sterling Specialty Pharmacy. Despite increased sales, marketing, and R&D expenses, the firm is optimistic about its trajectory, supported by a new national awareness campaign.
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. ET the same day to discuss the results and provide a business update. The company offers innovative contraceptive solutions, including Twirla®, a non-daily prescription contraceptive patch. Investors can access the call via the company's Investor Relations page.
Agile Therapeutics (Nasdaq: AGRX) announced that its Chairman and CEO, Al Altomari, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The event will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern Time on the Investors section of Agile's website. An archived version will remain accessible for 30 days. Agile Therapeutics focuses on women's healthcare, with its initial product, Twirla, a non-daily prescription contraceptive patch, utilizing proprietary Skinfusion technology.
Agile Therapeutics, Inc. (Nasdaq: AGRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 9:10 a.m. ET. The conference will be held virtually, allowing broader access for participants.
A live webcast of the presentation will be available on Agile's Investor Relations page, and an archived version will remain accessible for 30 days. Agile focuses on women's healthcare and offers contraceptive solutions via its Twirla® transdermal system, allowing women flexibility in their contraceptive choices without the need for daily pills.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
What is Agile Therapeutics' primary product?
How well did Agile Therapeutics perform financially in the third quarter of 2023?
What is Skinfusion® technology?
What are the company's future financial projections?
How is the company expanding its market presence?
What are the current trading circumstances of Agile Therapeutics' shares?
How did Agile Therapeutics manage their operational expenses?
What strategic initiatives is Agile Therapeutics currently pursuing?
What impact does the Biden-Harris Administration's new guidance have on Twirla?
Where can more information about Agile Therapeutics be found?
